Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$7.64
+7.9%
$6.78
$5.81
$14.38
$631.67M0.83399,140 shs603,873 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$12.90
+3.4%
$12.84
$3.80
$17.31
$154.03M0.5129,288 shs60,540 shs
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
$31.43
+4.4%
$37.45
$21.77
$81.56
$465.48M1.34687,265 shs847,315 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$18.95
+0.1%
$13.80
$8.15
$19.00
$534.39M2.2287,268 shs313,527 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
-1.80%-3.54%+9.94%+8.42%-22.37%
LENSAR, Inc. stock logo
LNSR
LENSAR
-0.64%-0.24%-4.59%-8.04%+178.35%
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
-3.56%-14.32%-25.11%-32.08%+2.49%
ZimVie Inc. stock logo
ZIMV
ZimVie
-0.16%+0.53%+1.07%+128.62%+9.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/AN/AN/AN/A
LENSAR, Inc. stock logo
LNSR
LENSAR
1.0715 of 5 stars
2.01.00.00.02.72.50.0
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
3.5446 of 5 stars
3.64.00.00.02.71.71.3
ZimVie Inc. stock logo
ZIMV
ZimVie
0.6895 of 5 stars
1.03.00.00.02.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.75
Moderate Buy$13.7579.97% Upside
LENSAR, Inc. stock logo
LNSR
LENSAR
2.00
Hold$15.0016.28% Upside
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
3.25
Buy$81.75160.10% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
2.00
Hold$17.75-6.33% Downside

Current Analyst Ratings Breakdown

Latest LNSR, BVS, SMLR, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2025
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$61.00 ➝ $60.00
7/31/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$19.00
7/28/2025
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$61.00
7/28/2025
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$61.00
7/22/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$9.00 ➝ $19.00
7/9/2025
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$95.00
7/8/2025
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$101.00
7/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$564.14M1.12$0.61 per share12.58$2.80 per share2.73
LENSAR, Inc. stock logo
LNSR
LENSAR
$53.49M2.88N/AN/A($1.93) per share-6.68
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
$56.29M8.27$4.51 per share6.97$25.90 per share1.21
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M1.19$1.86 per share10.21$14.64 per share1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23MN/AN/A16.61N/A-7.11%15.61%4.01%N/A
LENSAR, Inc. stock logo
LNSR
LENSAR
-$31.40M-$4.21N/AN/A-84.49%-737.30%-72.60%11/6/2025 (Estimated)
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
$40.90M$2.4312.93N/A86.20%43.84%32.88%11/3/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.70N/AN/A-4.39%6.37%3.34%10/29/2025 (Estimated)

Latest LNSR, BVS, SMLR, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.0750-$0.15-$0.0750-$0.15$16.55 million$11.36 million
8/4/2025Q2 2025
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
-$0.27$5.04+$5.31$5.04$8.10 million$8.22 million
7/30/2025Q2 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.2080$0.26+$0.0520-$0.14$112.60 million$116.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
1.52
0.88
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
0.25
0.60
0.58
ZimVie Inc. stock logo
ZIMV
ZimVie
0.56
2.37
1.60

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
49.37%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
LENSAR, Inc. stock logo
LNSR
LENSAR
38.52%
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
16.40%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.68 million54.46 millionNot Optionable
LENSAR, Inc. stock logo
LNSR
LENSAR
11011.94 million7.34 millionOptionable
Semler Scientific Inc. stock logo
SMLR
Semler Scientific
12014.81 million12.38 millionNot Optionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77028.20 million27.35 millionOptionable

Recent News About These Companies

ZimVie Board Unanimously Approves Transaction
ZimVie (NASDAQ:ZIMV) Sets New 12-Month High - What's Next?
ZimVie Reports Second Quarter 2025 Financial Results
Insights into ZimVie's Upcoming Earnings
ZimVie to sell to investment firm for about $730M

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioventus stock logo

Bioventus NYSE:BVS

$7.64 +0.56 (+7.91%)
Closing price 04:00 PM Eastern
Extended Trading
$7.64 0.00 (-0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

LENSAR stock logo

LENSAR NASDAQ:LNSR

$12.90 +0.43 (+3.45%)
Closing price 04:00 PM Eastern
Extended Trading
$12.90 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Semler Scientific stock logo

Semler Scientific NASDAQ:SMLR

$31.43 +1.33 (+4.42%)
Closing price 04:00 PM Eastern
Extended Trading
$31.59 +0.16 (+0.51%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$18.95 +0.02 (+0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$18.92 -0.03 (-0.15%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.